- Joined
- Jun 12, 2009
- Messages
- 70
- Reaction score
- 0
anybody have any local economic outcomes data on linezolid vs vanc in both skin and lung? all the data I can find is funded by pfizer. any insights about other data would be helpful. thanks
I suggest you do your own retrospective study comparing Vanc vs. Linezolid in pneumonia and SSI at your facility and how the LOS was affected.
I say this because I think one of the main predictors of the outcome is the MRSA MIC and this is can vary greatly from institution to institution. Of course you need to evaluate the MIC methodology and the accurach.
I would be interested in seeing your results. I want to begin a retro study to see the same thing, although my only issue is now we are starting to try telavancin now, and lack of patients may make it a little difficult to see true rates. Anyways let us know if you find anything.
anybody have any local economic outcomes data on linezolid vs vanc in both skin and lung? all the data I can find is funded by pfizer. any insights about other data would be helpful. thanks